The mechanism of BI905711

CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?

In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the […]

Blog 2024-04-19
The structure of Claudin proteins enables the Claudins tight protein family to effectively maintain the polarity of epithelial and endothelial cells.

Tumor Immune Target – Claudin18.2

Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]

Blog ,, 2024-04-18
ActRII signaling pathway

ActRII – A Novel Drug Target that Preserves Skeletal Muscle Mass and Enhances Fat Loss

In the previous article, we focused on the popular drug target for weight loss, G Protein-Coupled Receptor 75 (GPR75). This time, our topic is another emerging target for treating adult obesity, Activin A Receptor Type 2 (ActRII). Unlike currently approved weight loss drugs, which can reduce the weight of obese patients but often lead to […]

Blog , 2024-04-10
20-HETE Receptor (GPR75) Signaling in Endothelial Cells

GPR75 – An Emerging Target for Weight Loss Drugs

When it comes to weight loss medications, one cannot overlook the remarkable success of Semaglutide (GLP-1 weight loss drug), which has propelled the Danish biopharmaceutical company, Novo Nordisk, to new heights. According to Novo Nordisk’s financial report for 2023, Semaglutide sales reached $21.2 billion in 2023. On March 7th, Novo Nordisk’s stock price surged by […]

Blog , 2024-04-01
The structure of MUC1 gene (A) and protein (B)

MUC1 – What is its Potential in Cancer Therapy?

Mucin1 (MUC1), also known as MAM6 and EMA, is a surface mucin glycoprotein found to be highly expressed in epithelial-derived tumor tissues, such as lung cancer, pancreatic cancer, prostate cancer, epithelial ovarian cancer, and breast cancer. Its expression has been correlated with tumor metastasis and recurrence. Currently, MUC1 has attracted the attention of several pharmaceutical […]

Blog 2024-03-25
The structure of DLLs

DLL3 – A Target for Small Cell Lung Cancer Treatment

When it comes to DLL3, people immediately think of Rova-T, the ADC drug targeting the DLL3 receptor that dashed AbbVie’s $5.8 billion expectations. AbbVie’s setback had once caused a decline in the enthusiasm for DLL3-targeted treatments. However, the spotlight returned when Amgen unveiled the DLL3/CD3 bispecific antibody Tarlatamab data at the 2023 ESMO conference. On […]

Blog , 2024-03-07
The entire process of Single B Cell Cloing Technology consists of five main steps, including B cell collection, single B cell screening, antibody gene sequencing and analysis, recombinant antibody expression, and antibody function validation.

Understanding Single B Cell Cloning Technology in One Read

Antibody drugs, due to their high specificity and significant therapeutic effects, possess superior pharmacokinetic properties, making them a crucial player in the biopharmaceutical market. According to Frost & Sullivan’s statistical predictions, the global antibody drug market is expected to reach $443.1 billion by 2030. As the demand for antibody drugs continues to grow, the development […]

Blog 2024-02-27
Proposed role of HSD17B13 in modulating disease progression in NAFLD

HSD17B13-NASH Therapeutic Emerging Target

On November 30, 2023, Inipharm, a pharmaceutical company focused on severe liver diseases, announced the initiation of a Phase I clinical study for its oral drug INI-822. INI-822 is the first small molecule inhibitor of HSD17B13 to enter clinical development, and it is also the first clinical candidate developed by Inipharm, primarily intended for the […]

Blog 2024-02-19
The mechanism of ADC action

About ADC Toxins – Everything You Need to Know

Antibody-Drug Conjugates (ADCs) are a novel class of cancer drugs that combine three main components: a monoclonal antibody, a linker, and a toxin. By harnessing the specificity of antibodies and the potency of cytotoxic agents, ADCs can selectively target and kill tumor cells, while sparing healthy cells. The choice of toxin is critical for the […]

Blog 2024-02-02
The structure of GPC3

GPC3, a Popular Target in Liver Cancer Treatment

On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a chimeric antigen receptor T-cell (CAR-T) therapy targeting Glypican-3 (GPC3) for hepatocellular carcinoma (HCC). According to the agreement, AbelZeta is eligible for milestone payments and licensing fees for its global development. The drug will be exclusively developed, manufactured, and commercialized by […]

Blog 2024-01-24